| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	Increased offer price to $3.65 per share, a $0.55 per share increaseImproved offer unanimously approved by Revance Board of Dir...
 
																	Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charlesto...
 
																	Needham analyst Serge Belanger reiterates Revance Therapeutics (NASDAQ:RVNC) from Hold to Hold.
 
																	Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announce...
 
																	 
																	Barclays analyst Balaji Prasad maintains Revance Therapeutics (NASDAQ:RVNC) with a Equal-Weight and lowers the price target ...
 
																	Board of Directors of Revance Recommend Stockholders Tender their SharesJOHNSON CITY, Tenn., Dec. 12, 2024 /PRNewswire/ -- Crow...
 
																	Mizuho analyst Vamil Divan maintains Revance Therapeutics (NASDAQ:RVNC) with a Neutral and lowers the price target from $6.6...
